Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Fibroblast growth factor
biomarker
hepatocyte growth factor
immune checkpoint inhibitor
interleukine-12
non-small cell lung cancer
plasma
resistance
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Dec 2020
31 Dec 2020
Historique:
received:
09
11
2020
revised:
14
12
2020
accepted:
23
12
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
6
1
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). An unmet need remains for new biomarkers associated with ICIs. In this study, consecutive patients with advanced NSCLC treated with nivolumab or pembrolizumab were included. Plasma at ICIs initiation was prospectively collected and a multiplex ELISA assay testing 48 cytokines and growth factors was performed. Exploratory endpoints were the association between plasma biomarkers with outcome and grade III-IV immune related adverse events (irAEs). Thirty-five patients were included. Patients without clinical benefit (
Identifiants
pubmed: 33396187
pii: cancers13010097
doi: 10.3390/cancers13010097
pmc: PMC7795942
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Oncotarget. 2018 Feb 8;9(17):13682-13693
pubmed: 29568386
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Oncoimmunology. 2016 Jul 22;5(9):e1213934
pubmed: 27757309
Clin Cancer Res. 2010 Jan 1;16(1):174-83
pubmed: 20008840
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Int J Mol Sci. 2018 Nov 14;19(11):
pubmed: 30441809
J Thorac Oncol. 2017 Oct;12(10):1536-1543
pubmed: 28751245
Clin Cancer Res. 2010 Sep 15;16(18):4616-24
pubmed: 20679350
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Ann Oncol. 2016 Oct;27(10):1953-8
pubmed: 27502709
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Clin Cancer Res. 2018 Jun 15;24(12):2716-2718
pubmed: 29549160
Science. 1991 Feb 15;251(4995):802-4
pubmed: 1846706
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
Sci Rep. 2016 Jan 29;6:20090
pubmed: 26822379
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Dermatol Sci. 2019 Jan;93(1):33-40
pubmed: 30318169
Oncogene. 1991 Apr;6(4):501-4
pubmed: 1827664
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Thorac Oncol. 2012 Feb;7(2):272-80
pubmed: 22089117
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Oncotarget. 2017 May 16;8(42):71805-71816
pubmed: 29069748
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Clin Lung Cancer. 2017 Nov;18(6):682-691.e5
pubmed: 28549836
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Eur J Cancer. 2016 Jan;52:1-9
pubmed: 26623522
Clin Cancer Res. 2018 Sep 15;24(18):4579-4587
pubmed: 29898990
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Cancer Res. 1997 Feb 1;57(3):433-9
pubmed: 9012470
Cancer Res. 2008 Nov 15;68(22):9479-87
pubmed: 19010923
J Cell Physiol. 2007 Nov;213(2):316-25
pubmed: 17607709
Int J Cancer. 2006 Aug 1;119(3):477-83
pubmed: 16453287
Front Oncol. 2020 Feb 06;10:54
pubmed: 32117721
J Thorac Oncol. 2017 Mar;12(3):458-466
pubmed: 27815126
Ann Thorac Cardiovasc Surg. 2012;18(1):1-7
pubmed: 21959198